Archives
-
Renal Blood Flow and K+ Channels in Sepsis
2026-10-07
This study examined how ATP-sensitive and calcium-activated potassium-channel blockade alters renal vascular responses in septic rats exposed to norepinephrine or phenylephrine. Its main contribution is showing that channel blockade may preserve an abnormal pressor response in isolated kidneys yet worsen renal blood-flow reduction in vivo, underscoring the context dependence of sepsis pharmacology.
-
(S)-(+)-Methoprene: JH Signaling Evidence Guide
2026-10-07
(S)-(+)-Methoprene is a juvenile hormone analog used to examine Met-centered developmental signaling in arthropods. Evidence supports a conceptual distinction between receptor-driven responses and endogenous juvenile hormone biosynthesis, while the strongest mechanistic evidence remains species- and assay-dependent.
-
Staurosporine: Evidence, Principles and Limits
2026-10-06
A source-grounded overview of Staurosporine as a broad-spectrum serine/threonine protein kinase inhibitor, with emphasis on apoptosis research, evidence quality, tumor-microenvironment interpretation, and limits on translational claims.
-
miRNA–mRNA Control of Juvenile Hormone Biosynthesis
2026-10-06
A 2025 study in Insect Science identifies coordinated miRNA–mRNA modules that support juvenile hormone biosynthesis during locust vitellogenesis. Its combined transcriptomic, reporter-based, and perturbation evidence links post-transcriptional control of biosynthetic genes with vitellogenin expression and ovarian development, while also defining important limits for cross-species interpretation.
-
Macromolecular Cryoprotectants Improve THP-1 Recovery
2026-10-05
A 2025 RSC Applied Polymers study reports that macromolecular cryoprotectants, including polyampholytes and ice-nucleating components, improve post-thaw recovery of THP-1 monocytes in vial and multi-well formats. The evidence links better recovery to reduced intracellular ice formation and shows that macrophage-like differentiation can approach non-frozen controls, although broader functional transferability remains to be established.
-
Go 6983 in PKC Signaling: Evidence and Limits
2026-10-05
This overview separates supplier-reported pharmacology for Go 6983 from peer-reviewed findings on WDR36, glycolysis, and early embryonic lineage commitment. It evaluates conceptual uses in PKC signaling pathway research, cancer progression studies, and epithelial-to-mesenchymal transition research while emphasizing evidence provenance, selectivity limits, model boundaries, and the absence of direct evidence connecting Go 6983 to the WDR36 mechanism.
-
EGTA and Calcium Signaling: Evidence and Limits
2026-10-04
EGTA, also called egtazic acid, is an aminopolycarboxylic acid used to chelate calcium and study calcium-dependent biology. The 2026 Talin1 study links Piezo1-mediated calcium influx with endothelial inflammation, but it did not test EGTA as an intervention, so the study supports a mechanistic rationale rather than direct evidence for EGTA efficacy.
-
Beyond STING: A Translational View of Ferroptosis
2026-10-03
A source-grounded perspective on how H-151 links STING biology with ferroptosis, what the renal ischemia-reperfusion findings mean for translational strategy, and where ML-210 may fit as a hypothesis-testing research reagent.
-
Phenytoin for Sodium Channel Research
2026-10-02
Phenytoin provides a practical probe for connecting voltage-gated sodium channel behavior with biochemical counter-screens. This workflow combines electrophysiology, neurological disease models, and human paraoxonase-1 assays while highlighting solvent, concentration, and stability controls that protect data quality.
-
Cyclic di-GMP as an Antitoxin in Biofilm Persistence
2026-10-01
The 2024 eLife study by Liao, Yan and colleagues identifies cyclic di-GMP as a small-molecule antitoxin that restrains the genotoxic toxin HipH during biofilm development. Its findings connect adhesion-stage signaling with DNA double-strand breaks, genome instability, and antibiotic persistence, refining mechanistic models of biofilm resilience.
-
Go 6983: Testing PKC Control of Cell Fate
2026-10-01
A translational framework for using Go 6983 as a mechanistic pan-PKC inhibitor in cancer, EMT, and human blastoid research—while separating established evidence from testable hypotheses linking PKC activity, WDR36, glycolysis, and trophectoderm differentiation.
-
TP53 Mutation, FTH, and Ferroptosis in Glioblastoma
2026-09-30
The reference study identifies an iron-homeostasis mechanism linking TP53 gain-of-function signaling to reduced ferritin heavy chain (FTH), increased labile iron, and ferroptosis sensitivity in glioblastoma models. Its findings support a genotype-informed strategy in which iron loading and ferroptosis induction are studied together, while also highlighting the need to validate the mechanism in clinically representative tumor systems.
-
DNMT3B and Neuroendocrine Prostate Cancer Plasticity
2026-09-30
The reference study identifies DNMT3B as a driver of therapy-associated neuroendocrine lineage plasticity and stemness in prostate cancer. Genetic depletion and pharmacologic inhibition with Nanaomycin A reduced neuroendocrine prostate cancer growth in preclinical models, supporting DNMT3B as a candidate target for treatment-resistant disease.
-
H-151 Links STING Inhibition to Ferroptosis Control
2026-09-29
The reference study shows that H-151, traditionally used as a covalent STING inhibitor, also suppresses ferroptosis through STING-independent radical-trapping antioxidant activity. By combining inflammatory pathway inhibition with protection against lipid peroxidation, H-151 reduced renal ischemia-reperfusion injury in mice and provides a mechanistic rationale for dual-pathway intervention.
-
TP53, FTH, and Ferroptosis in Glioblastoma
2026-09-29
This study identifies a TP53 mutation–associated iron imbalance in glioblastoma in which increased ITCH expression promotes FTH degradation and raises intracellular free iron. The resulting state creates a potential ferroptosis vulnerability, particularly when iron loading is combined with Erastin, while also highlighting important limits of translating astrocyte and database findings into patient treatment strategies.